AstraZeneca (MEX:AZNN) Retained Earnings : MXN68,821 Mil (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is AstraZeneca Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AstraZeneca's retained earnings for the quarter that ended in Mar. 2025 was MXN68,821 Mil.

AstraZeneca's quarterly retained earnings increased from Sep. 2024 (MXN61,788 Mil) to Dec. 2024 (MXN65,904 Mil) and increased from Dec. 2024 (MXN65,904 Mil) to Mar. 2025 (MXN68,821 Mil).

AstraZeneca's annual retained earnings increased from Dec. 2022 (MXN-11,191 Mil) to Dec. 2023 (MXN25,495 Mil) and increased from Dec. 2023 (MXN25,495 Mil) to Dec. 2024 (MXN65,904 Mil).

AstraZeneca Retained Earnings Historical Data

The historical data trend for AstraZeneca's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Retained Earnings Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

105,407.71

35,078.94

-11,190.70

25,495.32

65,904.01

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Retained Earnings	Get a 7-Day Free Trial															-3,518.41	33,837.23	61,788.16	65,904.01	68,821.39

AstraZeneca Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

AstraZeneca (MEX:AZNN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (MEX:AZNN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNl:UK AZN:UK ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines